Tomoya Kurokawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomoya Kurokawa has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daiju Sakurai
Department of Otorhinolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan
1 shared publication Haruhiko Koseki
Affiliation Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
1 shared publicationHaruna Ebisu
Affiliation Clinical Research Center, Chiba University Hospital, Chiba, Chiba, Japan
1 shared publicationHideki Hanaoka
Affiliation Clinical Research Center, Chiba University Hospital, Chiba, Chiba, Japan
1 shared publication- Minami Koriyama1 shared publication
- Mitsuhiro Okano
Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by Elsevier in Allergology International
Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study
- 1 August 2026
- Published by Elsevier in Allergology International
Open AccessReal-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study
- Open Access
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342387
A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
Natural killer T (NKT) cells show intense tumor-killing activity through direct and indirect pathways. However, humans have less than 0.01% of NKT cells in the peripheral blood, making it difficult to apply NKT cells for cancer treatment. We have successfully produced invariant NKT cells derived from induced pluripotent stem cells (iPSC-iNKT cells) and demonstrated the tolerability of this product in a previous phase 1 clinical trial. Although the iPSC-iNKT cells showed substantial anti-tumor activity against various tumor cell types when combined with α-Galactosylceramide-pulsed autologous dendritic cells (DC/Gal) in non-clinical experiments, the tolerability of this combination therapy for humans has not demonstrated yet. Thus, we planned this first-in-human phase 1 open-label clinical trial to demonstrate data on tolerability and safety, as well as explore the immunological changes that occur following this combination treatment. We hypothesize that the sequential induction of nasal submucosal DC/Gal injection and intra-arterial administration of the iPSC-iNKT cells is tolerable and has a favorable safety profile for cancer patients. This trial provides vital and fundamental information for next-phase clinical trials and future applications of iPSC-iNKT cells for various cancer patients (jRCTa030220741; URL: https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030220741 ).
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342387
Open AccessA phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
Natural killer T (NKT) cells show intense tumor-killing activity through direct and indirect pathways. However, humans have less than 0.01% of NKT cells in the peripheral blood, making it difficult to apply NKT cells for cancer treatment. We have successfully produced invariant NKT cells derived from induced pluripotent stem cells (iPSC-iNKT cells) and demonstrated the tolerability of this product in a previous phase 1 clinical trial. Although the iPSC-iNKT cells showed substantial anti-tumor activity against various tumor cell types when combined with α-Galactosylceramide-pulsed autologous dendritic cells (DC/Gal) in non-clinical experiments, the tolerability of this combination therapy for humans has not demonstrated yet. Thus, we planned this first-in-human phase 1 open-label clinical trial to demonstrate data on tolerability and safety, as well as explore the immunological changes that occur following this combination treatment. We hypothesize that the sequential induction of nasal submucosal DC/Gal injection and intra-arterial administration of the iPSC-iNKT cells is tolerable and has a favorable safety profile for cancer patients. This trial provides vital and fundamental information for next-phase clinical trials and future applications of iPSC-iNKT cells for various cancer patients (jRCTa030220741; URL: https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030220741 ).